Key clinical point: Abrocitinib is safe and effective in patients with atopic dermatitis (AD) in daily practice, regardless of their previous inadequate response to upadacitinib or dupilumab.
Major finding: At week 28, 57.6% of patients achieved a ≥75% reduction in the Eczema Area and Severity Index (EASI) scores. At week 16, no significant difference was observed in the EASI scores between nonresponders and patients naive or responsive to upadacitinib or dupilumab (all P > .05). Most adverse events (81.6%) were mild in severity.
Study details: This multicenter prospective study included 103 patients with AD from the BioDay registry who did or did not exhibit adequate response to previous dupilumab or upadacitinib treatment and received abrocitinib for ≤28 weeks.
Disclosures: The BioDay registry was sponsored by Eli Lilly, Sanofi Genzyme, Leo Pharma, AbbVie, and Pfizer. Seven authors reported being consultants, speakers, etc., for or having other ties with various sources, including the aforementioned organizations. The other authors had nothing to disclose.
Source: Kamphuis E, Boesjes CM, Loman L, et al. Real-world experience of abrocitinib treatment in patients with atopic dermatitis and hand eczema: Up to 28-week results from the BioDay Registry. Acta Derm Venereol. 2024 (Feb 7). Doi: 10.2340/actadv.v104.19454 Source